| Literature DB >> 32413286 |
Ka Yang1, Yu Zhao1, Xueqing Nie1, Hao Wu1, Bo Wang1, Chelsi M Almodovar-Rivera1, Haibo Xie2, Weiping Tang3.
Abstract
Proteolysis-targeting chimeras (PROTACs) is a paradigm shift for small-molecule drug discovery. However, limited E3 ubiquitin ligase ligands with cellular activity are available. In vitro binding assays involve the expression and purification of a large amount of proteins and they often yield ligands that are inactive in cell-based assays due to poor cell permeability, stability, and other reasons. Herein, we report the development of a practical and efficient cell-based target engagement assay to evaluate the binding affinity of a small library of cereblon ligands to its E3 ligase in cells. Selected cell-permeable E3 ligase ligands derived from this assay are then used to construct HDAC6 degraders with cellular protein degradation activity. Because the assay does not involve any genetic engineering, it is relatively easy to transfer from one cell type to a different one.Entities:
Keywords: CRBN; E3 ligase; HDAC6; IMiD; Lenalidomide; PROTAC; Pomalidomide; Thalidomide; target engagement; targeted protein degradation
Mesh:
Substances:
Year: 2020 PMID: 32413286 PMCID: PMC7368820 DOI: 10.1016/j.chembiol.2020.04.008
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116